Telbivudine therapy at 12 to 30 weeks' gestation prevented mother-to-infant hepatitis B transmission, compared with 9% transmission in the control group, in a study of 88 pregnant women with high viral loads and alanine aminotransferase levels. Researchers reported that 77% of women who took the drug had normal ALT levels one month after giving birth, compared with 49% in the control group.
Telbivudine eliminates mother-to-child HBV transfer in study
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||